dc.contributor.author | Gansmo, Liv Beathe | |
dc.contributor.author | Romundstad, Pål Richard | |
dc.contributor.author | Birkeland, Einar Elvbakken | |
dc.contributor.author | Hveem, Kristian | |
dc.contributor.author | Vatten, Lars Johan | |
dc.contributor.author | Knappskog, Stian | |
dc.contributor.author | Lønning, Per Eystein | |
dc.date.accessioned | 2016-03-08T11:15:45Z | |
dc.date.accessioned | 2016-05-11T08:37:10Z | |
dc.date.available | 2016-03-08T11:15:45Z | |
dc.date.available | 2016-05-11T08:37:10Z | |
dc.date.issued | 2015-10-16 | |
dc.identifier.citation | Cancer Medicine 2015, 4(12):1901-1907 | nb_NO |
dc.identifier.issn | 2045-7634 | |
dc.identifier.uri | http://hdl.handle.net/11250/2388996 | |
dc.description.abstract | The MDM4 protein plays an important part in the negative regulation of the
tumor suppressor p53 through its interaction with MDM2. In line with this,
MDM4 amplification has been observed in several tumor forms. A polymorphism
(rs4245739 A>C; SNP34091) in the MDM4 3′ untranslated region has been
reported to create a target site for hsa-miR-
191,
resulting in decreased MDM4
mRNA levels. In this population-based
case–control study, we examined the
potential association between MDM4 SNP34091, alone and in combination with
the MDM2 SNP309T>G (rs2279744), and the risk of breast-,
colon-,
lung-,
and
prostate cancer in Norway. SNP34091 was genotyped in 7,079 cancer patients
as well as in 3,747 gender-and
age-matched
healthy controls. MDM4 SNP34091C
was not associated with risk for any of the tumor forms examined, except for
a marginally significant association with reduced risk for breast cancer in a
recessive model (OR = 0.77: 95% CI = 0.59–0.99). Stratifying according to
MDM2 SNP309 status, we observed a reduced risk for breast cancer related to
MDM4 SNP34091CC among individuals harboring the MDM2 SNP309GG genotype
(OR = 0.41; 95% CI = 0.21–0.82). We conclude, MDM4 SNP34091 status
to be associated with reduced risk of breast cancer, in particular in individuals
carrying the MDM2 SNP309GG genotype, but not to be associated with either
lung-,
colon-or
prostate cancer. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Wiley Open Access | nb_NO |
dc.relation.uri | http://onlinelibrary.wiley.com/doi/10.1002/cam4.555/epdf | |
dc.rights | Navngivelse 3.0 Norge | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/no/ | * |
dc.title | MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung- and prostate cancer risk. | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.date.updated | 2016-03-08T11:15:45Z | |
dc.source.pagenumber | 1901-1907 | nb_NO |
dc.source.volume | 4 | nb_NO |
dc.source.journal | Cancer Medicine | nb_NO |
dc.source.issue | 12 | nb_NO |
dc.identifier.doi | 10.1002/cam4.555 | |
dc.identifier.cristin | 1340513 | |
dc.description.localcode | © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | nb_NO |